Matthew Reber

Matthew joined 1315 Capital as Partner in 2017, bringing extensive healthcare investing experience across debt and equity transactions. Prior to joining 1315 Capital, he spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of Codis, Experic, Medivant Healthcare, Primrose Bio, ProSciento, SciSafe, USpharma, and previously served on the board of Reaction Biology (acquired by Cobepa) and Verogen (acquired by QIAGEN). Matthew also serves on the Board of Directors of Life Sciences Pennsylvania.

Matthew has over two decades of growth stage investing experience with a focus on the pharma/medtech outsourcing and pharma/medtech product sectors. Prior to HealthCare Royalty Partners, Matthew worked at Accretive LLC and Paul Capital Partners.  Earlier in his career, he worked as a principal investor focused on the healthcare industry at Oak Hill Capital Partners and J.H. Whitney & Co.  Matthew started his career as a healthcare investment banker at Morgan Stanley. Matthew has worked on over $1 billion in healthcare financings over the course of his career.

Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania.